| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Complex polysaccharides and glycosides. Snailase targets beta‑glycosidic bonds in plant cell wall components and flavonoid glycosides. Its various enzymes have distinct substrates: cellulase hydrolyzes cellulose, pectinase degrades pectin, and glycosidases cleave sugar moieties from flavonoids, releasing aglycones.
|
|---|---|
| ln Vitro |
Snailase hydrolyzes purified flavonoid glycosides (e.g., rutin, naringin, hesperidin) into their aglycone forms (quercetin, naringenin, hesperetin). The enzyme mixture (1-10 mg/mL; pH 4.5-5.5; 37-50degC) efficiently cleaves the glycosidic bonds of various flavonoids, with conversion rates exceeding 90% within 12-24 hours, depending on the substrate.
|
| ln Vivo |
Snailase is not typically used for in vivo applications due to it being an exogenous enzyme mixture. However, it has been utilized in animal studies to pre‑digest feed components or to produce bioactive aglycones for subsequent oral administration. Indirectly, it may be used in ex vivo experiments to generate metabolites from plant extracts prior to testing in animal models.
|
| Enzyme Assay |
Snailase is dissolved in acetate buffer (0.1 M, pH 4.5-5.5) at a concentration of 5-20 mg/mL. For glycoside hydrolysis, a reaction mixture containing 1-10 mg of flavonoid glycoside and 0.5-2 mL of Snailase solution is incubated at 37-50degC for 6-24 hours with gentle shaking. The reaction is stopped by heating at 100degC for 5 minutes. The products (aglycones) are extracted with ethyl acetate and analyzed by HPLC or LC-MS. No receptor binding assays are applicable.
|
| Cell Assay |
A typical protocol: 1 mg of flavonoid glycoside (e.g., rutin) is dissolved in 1 mL of 0.1 M acetate buffer (pH 5.0). Snailase (5-10 mg) is added, and the mixture is incubated at 40degC for 12-24 hours. Samples (100 uL) are taken at 0, 2, 4, 8, 12, and 24 hours, heat‑inactivated, and centrifuged. The supernatant is analyzed by HPLC with UV detection (e.g., 254 nm for flavonoids). Peak areas of the glycoside and aglycone are quantified to calculate conversion rates and enzyme kinetics (Km, Vmax).
|
| Animal Protocol |
Snailase is not directly administered to animals. Instead, in a pre‑digestion study, flavonoid glycosides are first hydrolyzed with Snailase (10 mg/mL, 40degC, 24 hours). The resulting aglycone-rich extract is then administered to rats or mice via oral gavage at a dose equivalent to 50-200 mg/kg of the original glycoside. Blood samples are collected over 24 hours, and plasma is analyzed for aglycone levels by LC-MS to compare bioavailability with the intact glycoside.
|
| ADME/Pharmacokinetics |
Snailase itself is an enzyme mixture and does not have typical drug-like pharmacokinetics. When used ex vivo to hydrolyze substrates, its activity is temperature‑ and pH‑dependent. It is not absorbed systemically. The aglycone products generated by Snailase hydrolysis exhibit their own PK properties, which vary by compound.
|
| Toxicity/Toxicokinetics |
Snailase is considered non‑toxic for its intended ex vivo use. It is generally recognized as safe for food processing applications. Direct administration of Snailase to animals is not standard practice; therefore, toxicological data are not required. Allergic reactions to snail proteins are theoretically possible but not documented for this research use.
|
| References |
[1]. Kornpointner C, et al. Snailase: A Promising Tool for the Enzymatic Hydrolysis of Flavonoid Glycosides From Plant Extracts. Front Plant Sci. 2022 Jun 9;13:889184.
|
| Additional Infomation |
Snailase is a complex enzyme mixture primarily sourced from the digestive juice of snails (Helix pomatia). It is also referred to as snail gastrointestinal enzyme. This mixture is used to degrade plant cell walls, release intracellular contents, and hydrolyze flavonoid glycosides to their more bioavailable aglycones. It is available as a light brown to brown solid powder. Snailase is not approved for clinical use; it is strictly a research and industrial reagent. Molecular composition is variable; no single molecular formula applies.
|
| CAS # |
158736-45-9
|
|---|---|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 3.33 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
